Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to <6 years. In an open‐la...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Hepatology
Главные авторы: Schwarz, Kathleen B., Rosenthal, Philip, Murray, Karen F., Honegger, Jonathan R., Hardikar, Winita, Hague, Rosie, Mittal, Naveen, Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Narkewicz, Michael R., Rao, Girish S., Whitworth, Suzanne, Bansal, Sanjay, Balistreri, William F.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2019
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7028138/
https://ncbi.nlm.nih.gov/pubmed/31220349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30830
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы